Literature DB >> 7530484

Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer.

M L Cher1, D MacGrogan, R Bookstein, J A Brown, R B Jenkins, R H Jensen.   

Abstract

Due to problems with primary tumor cell culture, conventional cytogenetics has yielded little insightful information on chromosomal alterations in prostate cancer. The primary aim of this study was to define the ability of comparative genomic hybridization (CGH) to detect and map genetic deletions in prostate tumors. A secondary aim was to apply multiple assays to individual tumors as a means of deciphering the mechanisms of genetic alterations in prostate cancer. CGH results were compared with allelic imbalance measurements at 29 distinct loci on chromosome 8 in 18 specimens (17 malignant and 1 benign). CGH detected no changes in cases where all informative PCR/RFLP loci were retained and detected all p arm deletions consisting of at least two loci. We estimate that in this study, the smallest deletions detected by CGH were approximately 20-30 cM. Physical mapping of subchromosomal arm deletions by CGH correlated well with allelic imbalance mapping by PCR/RFLP: The data agreed at 88% of loci on 8p and 92% of loci on 8q. Fluorescence in situ hybridization (FISH) with multiple centromere probes and DNA content flow cytometry (FCM) also was performed on selected specimens. FISH revealed two cases of chromosome 8 aneusomy. In these two cases and three others, CGH showed simultaneous p arm deletion and q arm gain, suggesting isochromosome 8q formation. Together, these data suggested that, simple chromosomal aberrations were responsible for allelic losses on 8p and allelic gains on 8q in a significant number of prostate tumors. We also used CGH to examine relative DNA sequence copy number throughout the genome. Changes frequently associated with 8p loss include gains of 8q and losses of 13q, 16p, 16q, 17p, 17q, 20q, and Y. Cases with 8p loss exhibited five times the number of alterations as did cases without 8p loss.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7530484     DOI: 10.1002/gcc.2870110304

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  34 in total

1.  The impact of genomic alterations on the transcriptome: a prostate cancer cell line case study.

Authors:  J Chaudhary; M Schmidt
Journal:  Chromosome Res       Date:  2006-07-12       Impact factor: 5.239

2.  Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer.

Authors:  S F Huang; S Xiao; A A Renshaw; K R Loughlin; T J Hudson; J A Fletcher
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 3.  Advances in cytogenetic analysis of solid tumours.

Authors:  L James; J Varley
Journal:  Chromosome Res       Date:  1996-11       Impact factor: 5.239

4.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer.

Authors:  R E Reiter; Z Gu; T Watabe; G Thomas; K Szigeti; E Davis; M Wahl; S Nisitani; J Yamashiro; M M Le Beau; M Loda; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

5.  Clinical Correlates of Autosomal Chromosomal Abnormalities in an Electronic Medical Record-Linked Genome-Wide Association Study: A Case Series.

Authors:  Hayan Jouni; Khader Shameer; Yan W Asmann; Ribhi Hazin; Mariza de Andrade; Iftikhar J Kullo
Journal:  J Investig Med       Date:  2013-10       Impact factor: 2.895

6.  Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study.

Authors:  Jennifer A Byrne; Yuyan Chen; Nancy Martin La Rotta; Gregory B Peters
Journal:  Genes Cancer       Date:  2012-02

7.  The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors.

Authors:  H Ishii; R Baffa; S I Numata; Y Murakumo; S Rattan; H Inoue; M Mori; V Fidanza; H Alder; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

8.  Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer.

Authors:  Norihiko Tsuchiya; Yasushi Kondo; Atsushi Takahashi; Hemant Pawar; Junqi Qian; Kazunari Sato; Michael M Lieber; Robert B Jenkins
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

Review 9.  Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy.

Authors:  Amelia A Glazier; Andrea Thompson; Sharlene M Day
Journal:  Pflugers Arch       Date:  2018-11-20       Impact factor: 3.657

10.  Defining aggressive prostate cancer using a 12-gene model.

Authors:  Tarek A Bismar; Francesca Demichelis; Alberto Riva; Robert Kim; Sooryanarayana Varambally; Le He; Jeff Kutok; Jonathan C Aster; Jeffery Tang; Rainer Kuefer; Matthias D Hofer; Phillip G Febbo; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2006-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.